Oncoethix | Site

Oncoethix is a clinical stage biotechnology company developing innovative cancer drugs.

Oncoethix’s product pipeline includes three first-in-class agents to novel cancer targets or with novel mode of action. Two of these agents are in clinical development.

2013 31 January

PATIENT IN ITS PHASE 1 TRIAL OF OTX015

OncoEthix Doses First Patient in its Phase I Trial of OTX015, a BET Bromodomain inhibitor for the Treatment of Hematologic Malignancies
2012 3 December

Article on Oncoethix Strategy

BioCentury The Bernstein Report on BioBusiness, December 3, 2012,
Strategy article on Oncoethix S.A. entitled “Replicate, then license”.
2012 21 November

Oncoethix announces receipt of FDA Clearance

Oncoethix announces receipt of FDA Clearance to proceed with a Phase 1 Study of OTX015

all news read more

About Us

Product Pipeline

News

PATIENT IN ITS PHASE 1 TRIAL OF OTX015

Article on Oncoethix Strategy

Oncoethix announces receipt of FDA Clearance